BioSpace News Archive

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to announce the recipients of their 2022 Health Equity and Inclusiveness Research Awards.

CHADD is proud to announce the appointment of Laurie Kulikosky, CAE, as the organization’s new Chief Executive Officer, effective October 17, 2022.

Alterity Therapeutics today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

OpGen, Inc. announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing from blood culture samples in low and middle income countries.

ImmuneSensor Therapeutics Inc. announced the Company has been awarded a $16.1 million Product Development Research Grant from the Cancer Prevention and Research Institute of Texas to advance Phase 2 studies evaluating IMSA101, a STING agonist, in combination with immune checkpoint inhibitors and radiotherapy for the treatment of metastatic solid tumor malignancies.

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. today announced the European Commission (EC) has granted marketing authorization for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive update to the ongoing Phase 1b/2a SELECT-HD clinical trial of WVE-003, the company’s clinical candidate for Huntington’s disease (HD).

Generation Bio Co. announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.

Gain Therapeutics, Inc. today announced that Matthias Alder, the Company’s current Chief Operating Officer, has been appointed as the Company’s Chief Executive Officer, effective immediately.

Biomea Fusion, Inc. presented today “Oral menin inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a type 2 diabetes rat model”, the first of two oral presentations at the EASD Annual Meeting.